Jan Stoehlmacher
Overview
Explore the profile of Jan Stoehlmacher including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
2569
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Noepel-Duennebacke S, Juette H, Schulmann K, Graeven U, Porschen R, Stoehlmacher J, et al.
J Cancer Res Clin Oncol
. 2021 Mar;
147(10):3063-3072.
PMID: 33675399
Introduction: In a retrospective analysis of two randomized phase III trials in mCRC patients treated first line with oxaliplatin, fluoropyrimidine with and without Bevacizumab (the AIO KRK 0207 and R091...
2.
Al-Batran S, Homann N, Pauligk C, Goetze T, Meiler J, Kasper S, et al.
Lancet
. 2019 Apr;
393(10184):1948-1957.
PMID: 30982686
Background: Docetaxel-based chemotherapy is effective in metastatic gastric and gastro-oesophageal junction adenocarcinoma. This study reports on the safety and efficacy of the docetaxel-based triplet FLOT (fluorouracil plus leucovorin, oxaliplatin and...
3.
Al-Batran S, Homann N, Pauligk C, Illerhaus G, Martens U, Stoehlmacher J, et al.
JAMA Oncol
. 2017 Apr;
3(9):1237-1244.
PMID: 28448662
Importance: Surgical resection has a potential benefit for patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction. Objective: To evaluate outcome in patients with limited metastatic disease who receive...
4.
Hegewisch-Becker S, Graeven U, Lerchenmuller C, Killing B, Depenbusch R, Steffens C, et al.
Lancet Oncol
. 2015 Sep;
16(13):1355-69.
PMID: 26361971
Background: The definition of a best maintenance strategy following combination chemotherapy plus bevacizumab in metastatic colorectal cancer is unclear. We investigated whether no continuation of therapy or bevacizumab alone are...
5.
Schuette W, Behringer D, Stoehlmacher J, Kollmeier J, Schmager S, Fischer von Weikersthal L, et al.
Clin Lung Cancer
. 2015 Jun;
16(6):447-56.
PMID: 26094080
Introduction: The aim of the study was to investigate the efficacy and tolerability of panitumumab, a fully human antiepidermal growth factor receptor monoclonal antibody, in combination with pemetrexed/cisplatin in patients...
6.
Schwarzenbach H, Goekkurt E, Pantel K, Aust D, Stoehlmacher J
Int J Cancer
. 2009 Dec;
127(4):881-8.
PMID: 19998340
As a key enzyme in folate metabolism, the thymidylate synthase (TS) is important for the synthesis of nucleotides. Its polymorphisms may affect the TS gene expression and the susceptibility for...
7.
Folprecht G, Gruenberger T, Bechstein W, Raab H, Lordick F, Hartmann J, et al.
Lancet Oncol
. 2009 Nov;
11(1):38-47.
PMID: 19942479
Background: Neoadjuvant chemotherapy for unresectable colorectal liver metastases can downsize tumours for curative resection. We assessed the effectiveness of cetuximab combined with chemotherapy in this setting. Methods: Between Dec 2,...
8.
Mogck U, Goekkurt E, Stoehlmacher J
Methods Mol Biol
. 2009 Nov;
576:341-50.
PMID: 19882270
Tumor-specific and germ-line variations of DNA significantly contribute to tumor growth and its ability to develop resistance. Among several mechanisms that cause resistance to cancer treatment, the genotype of certain...
9.
Goekkurt E, Al-Batran S, Hartmann J, Mogck U, Schuch G, Kramer M, et al.
J Clin Oncol
. 2009 Apr;
27(17):2863-73.
PMID: 19332728
Purpose: To evaluate the association of germ-line polymorphisms of genes that may impact treatment outcome of platinum and fluorouracil combination chemotherapy in advanced gastric cancer (AGC). Patients And Methods: Blood...
10.
Platzbecker U, von Bonin M, Goekkurt E, Radke J, Binder M, Kiani A, et al.
Biol Blood Marrow Transplant
. 2009 Jan;
15(1):101-8.
PMID: 19135948
A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of sirolimus, seems to mediate antileukemia...